Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high ...

The FDA approves the Embrace Hydrogel Embolic System, offering a groundbreaking treatment for hypervascular tumors in ...

During a live event, Matthew Lunning, DO, and participants discussed the process of determining if patients with DLBCL should ...

FDA accepts a new formulation of piflufolastat F 18, enhancing prostate cancer imaging access and efficiency, with a target ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment ...

FDA expands tocilizumab-anoh's indication for treating cytokine release syndrome, enhancing treatment options for patients ...

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this ...

The RESONATE-2 trial reveals ibrutinib's long-term efficacy and safety in treating CLL/SLL, especially for high-risk patients ...

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting ...

FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for ...

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...